The company signaled its clinical progress in May by dosing the first patients in a Phase 1 trial for 710GO, its primary candidate for general obesity. This move follows the startup’s emergence from stealth in March, a transition that marked its separation from its former parent, Endevica Bio. Endevica previously secured $10 million in Series B funding in early 2023 to support its research pipeline.

Kalohexis confirmed the confidential S-1 submission via a brief press release, withholding financial specifics and the names of underwriters. Further details regarding the company’s capitalization, share structure, and banking partners will emerge once the firm moves to a public filing.